These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Pegylated interferon alpha 2b and ribavirin in HIV/hepatitis C virus-co-infected non-responders and relapsers to IFN-based therapy. Myers RP, Benhamou Y, Bochet M, Thibault V, Mehri D, Poynard T. AIDS; 2004 Jan 02; 18(1):75-9. PubMed ID: 15090832 [Abstract] [Full Text] [Related]
3. Efficacy of pegylated interferon and ribavirin for retreatment of chronic HCV infection in HIV co-infected patients failing a previous standard interferon-based regimen. Crespo M, Mira JA, Pineda JA, Van den Eynde E, Ríos-Villegas MJ, Collado A, Girón-González JA, López-Cortés LF, González-Serrano M, Rivero A, Merino D, Esteban JI. J Antimicrob Chemother; 2008 Oct 02; 62(4):793-6. PubMed ID: 18567911 [Abstract] [Full Text] [Related]
5. Effect of aging, glucose level, and HIV viral load on response to treatment with pegylated interferon plus ribavirin in HIV/HCV co-infected women. Nasta P, Maida I, Cattelan AM, Pontali E, Angeli E, Giralda M, Verucchi G, Caputo A, Iannacone C, Puoti M, Carosi G. J Womens Health (Larchmt); 2015 Feb 02; 24(2):159-64. PubMed ID: 25682817 [Abstract] [Full Text] [Related]
7. Undetectable hepatitis C virus RNA at week 4 as predictor of sustained virological response in HIV patients with chronic hepatitis C. Martin-Carbonero L, Nuñez M, Mariño A, Alcocer F, Bonet L, García-Samaniego J, López-Serrano P, Cordero M, Portu J, Soriano V. AIDS; 2008 Jan 02; 22(1):15-21. PubMed ID: 18090387 [Abstract] [Full Text] [Related]
8. Efficacy and safety of peg-IFN alfa-2a with ribavirin for the treatment of HCV/HIV coinfected patients who failed previous IFN based therapy. Rodríguez-Torres M, Rodríguez-Orengo JF, Ríos-Bedoya CF, Fernández-Carbia A, González-Lassalle E, Salgado-Mercado R, Marxuach-Cuétara AM. J Clin Virol; 2007 Jan 02; 38(1):32-8. PubMed ID: 17064957 [Abstract] [Full Text] [Related]
9. Response-guided therapy for chronic hepatitis C virus infection in patients coinfected with HIV: a pilot trial. Van den Eynde E, Crespo M, Esteban JI, Jardi R, Ribera E, Carbonell J, Rodríguez-Frias F, Falco V, Curran A, Imaz A, Villar del Saz S, Ocaña I, Esteban R, Pahissa A. Clin Infect Dis; 2009 Apr 15; 48(8):1152-9. PubMed ID: 19275492 [Abstract] [Full Text] [Related]
10. Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial. Carrat F, Bani-Sadr F, Pol S, Rosenthal E, Lunel-Fabiani F, Benzekri A, Morand P, Goujard C, Pialoux G, Piroth L, Salmon-Céron D, Degott C, Cacoub P, Perronne C, ANRS HCO2 RIBAVIC Study Team. JAMA; 2004 Dec 15; 292(23):2839-48. PubMed ID: 15598915 [Abstract] [Full Text] [Related]
18. A Lead-In with Silibinin Prior to Triple-Therapy Translates into Favorable Treatment Outcomes in Difficult-To-Treat HIV/Hepatitis C Coinfected Patients. Braun DL, Rauch A, Aouri M, Durisch N, Eberhard N, Anagnostopoulos A, Ledergerber B, Müllhaupt B, Metzner KJ, Decosterd L, Böni J, Weber R, Fehr J, Swiss HIV Cohort Study. PLoS One; 2015 Dec 15; 10(7):e0133028. PubMed ID: 26176696 [Abstract] [Full Text] [Related]